A Phase l, Open-label, First in Human, Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

Trial Profile

A Phase l, Open-label, First in Human, Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2018

At a glance

  • Drugs NSI 566 (Primary) ; NSI 566 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; First in man
  • Sponsors Neuralstem
  • Most Recent Events

    • 03 May 2018 According to a Neuralstem media release, results of post-hoc comparison of combined cohorts from Phase 1 and 2 trials vs. historical controls were published in the Annals of Clinical and Translational Neurology.
    • 27 Jan 2016 According to a Neuralstem media release, data from this study was presented at the Phacilitate Cell & Gene Therapy World Conference, Washington D.C.
    • 29 Sep 2015 Results presented for 9 month phase II and combined phase I and phase II data presented at the American Neurological Association Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top